Thus, pharmacological blockade of HSP90 can overcome signaling redundancies and mechanisms of drug resistance commonly observed in many cancers and simultaneously targets two major tumor maintenance pathways in prostate cancer cells, the PI3K-AKT-mTOR and AR pathways. This evidence concerns the gene HSP90AB1 and neoplasm.